128 related articles for article (PubMed ID: 1897286)
1. [Pharmacokinetic aspects of tuberculosis therapy with a fixed combination of rifampicin, isoniazide and pyrazinamide].
Schaberg T; Lode H
Z Gesamte Inn Med; 1991 Jun; 46(8):276-9. PubMed ID: 1897286
[TBL] [Abstract][Full Text] [Related]
2. Comparative bioavailability of rifampicin, isoniazid and pyrazinamide from a four drug fixed dose combination with separate formulations at the same dose levels.
Agrawal S; Singh I; Kaur KJ; Bhade SR; Kaul CL; Panchagnula R
Int J Pharm; 2004 May; 276(1-2):41-9. PubMed ID: 15113612
[TBL] [Abstract][Full Text] [Related]
3. Bioavailability of isoniazid, rifampicin and pyrazinamide (in free combination or fixed-triple formulation) in intermittent antituberculous chemotherapy.
Acocella G; Luisetti M; Grassi GG; Peona V; Pozzi E; Grassi C
Monaldi Arch Chest Dis; 1993; 48(3):205-9. PubMed ID: 8369784
[TBL] [Abstract][Full Text] [Related]
4. [Tisamide in the complex treatment of tuberculosis].
Onishchenko VV; Sokolova GB; Koriakin VA; Shapatava MN; Iurchenko LN
Probl Tuberk; 1990; (7):43-5. PubMed ID: 2235951
[TBL] [Abstract][Full Text] [Related]
5. [Short-term therapy of lung tuberculosis using a fixed combination of isoniazid, rifampicin and pyrazinamide. Results after 2 years].
Brändli O; Haegi V; Villiger B; Bohn W; Baumann HR; Zäch R
Schweiz Med Wochenschr; 1989 Mar; 119(10):299-305. PubMed ID: 2652281
[TBL] [Abstract][Full Text] [Related]
6. The pharmacokinetic factors and bioavailability of rifampicin, isoniazid and pyrazinamid fixed in one dose capsule.
Zwolska Z; Augustynowicz-Kopeć E; Niemirowska-Mikulska H
Acta Pol Pharm; 2002; 59(6):448-52. PubMed ID: 12669769
[TBL] [Abstract][Full Text] [Related]
7. Oral solid lipid nanoparticle-based antitubercular chemotherapy.
Pandey R; Sharma S; Khuller GK
Tuberculosis (Edinb); 2005; 85(5-6):415-20. PubMed ID: 16256437
[TBL] [Abstract][Full Text] [Related]
8. [In 76% of patients with active tuberculosis treated with triple therapy (isoniazid-rifampicin-pyrazinamide) cultural conversion precedes microscopic conversion].
Nowak D; Radenbach D; Magnussen H
Pneumologie; 1990 Feb; 44 Suppl 1():497-8. PubMed ID: 2114634
[TBL] [Abstract][Full Text] [Related]
9. Pyrazinamide serum levels in childhood tuberculosis.
Thee S; Detjen A; Wahn U; Magdorf K
Int J Tuberc Lung Dis; 2008 Sep; 12(9):1099-101. PubMed ID: 18713511
[TBL] [Abstract][Full Text] [Related]
10. Rationale and experimental data in support of the use of a fixed-triple combination of isoniazid, rifampicin and pyrazinamide in the chemotherapy of tuberculosis.
Acocella G
G Ital Chemioter; 1987; 34(1-3):3-5. PubMed ID: 3504412
[No Abstract] [Full Text] [Related]
11. Pharmacokinetics of isoniazid in pulmonary tuberculosis--a comparative study at two dose levels.
Roy V; Tekur U; Chopra K
Indian Pediatr; 1996 Apr; 33(4):287-91. PubMed ID: 8772902
[TBL] [Abstract][Full Text] [Related]
12. [Controlled trial of isoniazid.rifampicin.ethambutol regimen and isoniazid.rifampicin.pyrazinamide regimen in the primary chemotherapy for pulmonary tuberculosis (author's transl)].
Kekkaku; 1980 Jan; 55(1):7-13. PubMed ID: 6988627
[No Abstract] [Full Text] [Related]
13. Bioavailability of rifampicin, isoniazid and pyrazinamide from fixed-dose combination capsules.
Zwolska Z; Niemirowska-Mikulska H; Augustynowicz-Kopec E; Walkiewicz R; Stambrowska H; Safianowska A; Grubek-Jaworska H
Int J Tuberc Lung Dis; 1998 Oct; 2(10):824-30. PubMed ID: 9783530
[TBL] [Abstract][Full Text] [Related]
14. Isoniazid, rifampicin and pyrazinamide plasma concentrations 2 and 6 h post dose in patients with pulmonary tuberculosis.
Fahimi F; Tabarsi P; Kobarfard F; Bozorg BD; Goodarzi A; Dastan F; Shahsavari N; Emami S; Habibi M; Salamzadeh J
Int J Tuberc Lung Dis; 2013 Dec; 17(12):1602-6. PubMed ID: 24200276
[TBL] [Abstract][Full Text] [Related]
15. Comparative bioavailability of isoniazid, rifampin, and pyrazinamide administered in free combination and in a fixed triple formulation designed for daily use in antituberculosis chemotherapy. I. Single-dose study.
Acocella G; Nonis A; Gialdroni-Grassi G; Grassi C
Am Rev Respir Dis; 1988 Oct; 138(4):882-5. PubMed ID: 3202464
[TBL] [Abstract][Full Text] [Related]
16. Bioequivalence assessment of rifampicin, isoniazid and pyrazinamide in a fixed dose combination of rifampicin, isoniazid, pyrazinamide and ethambutol vs. separate formulations.
Agrawal S; Singh I; Kaur KJ; Bhade SR; Kaul CL; Panchagnula R
Int J Clin Pharmacol Ther; 2002 Oct; 40(10):474-81. PubMed ID: 12395981
[TBL] [Abstract][Full Text] [Related]
17. [Clinico-pharmacokinetic interactions of rifampicin, pyrazinamide and isoniazide].
Musch E; Loos U; Schwabe HK
Pneumologie; 1990 Feb; 44 Suppl 1():486-7. PubMed ID: 2367444
[TBL] [Abstract][Full Text] [Related]
18. Bioavailability of rifampicin, isoniazid and pyrazinamide in a triple drug formulation: comparison of plasma and urine kinetics.
Gurumurthy P; Ramachandran G; Vijayalakshmi S; Kumar AK; Venkatesan P; Chandrasekaran V; Vjayasekaran V; Kumaraswami V; Prabhakar R
Int J Tuberc Lung Dis; 1999 Feb; 3(2):119-25. PubMed ID: 10091876
[TBL] [Abstract][Full Text] [Related]
19. A pilot stability study on four-drug fixed-dose combination anti-tuberculosis products.
Singh S; Mohan B
Int J Tuberc Lung Dis; 2003 Mar; 7(3):298-303. PubMed ID: 12661847
[TBL] [Abstract][Full Text] [Related]
20. The effect of pyrazinamide and rifampicin on isoniazid metabolism in rats.
De Rosa HJ; Baldan HM; Brunetti IL; Ximenes VF; Machado RG
Biopharm Drug Dispos; 2007 Sep; 28(6):291-6. PubMed ID: 17571294
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
